Topical treatment of basal cell carcinoma with neomycin.
Basal cell carcinoma (BCC) is the most common skin cancer, occurring more frequently than malignancies of any other tissue or organ, either individually or in total. Medical treatment modalities of BCC offer cost reduction and clinical advantages in selected cases. Neomycin has been reported to have an important role on proliferation of endothelial cells and neoplastic cells. This finding may lead to new strategies for the therapeutic use of agents which block FGF activities in disease states associated with enhanced keratinocyte proliferation. We report here a case of BCC treated with neomycin 5% cream that induced a regression of BCC.
Cuevas
P
P
Department of Research, Hospital Ramón y Cajal, Madrid, Spain. pedro.cuevas@hrc.es
Arrazola
J M
JM
D000287:Administration, Topical; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005142:Eyelid Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage*; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*
D011500:Protein Synthesis Inhibitors; D009355:Neomycin